tiprankstipranks
Consun Pharmaceutical Advances with New Drug Approvals
Company Announcements

Consun Pharmaceutical Advances with New Drug Approvals

Consun Pharmaceutical Group Ltd. (HK:1681) has released an update.

Don't Miss Our Christmas Offers:

Consun Pharmaceutical Group Ltd. has announced the National Medical Products Administration’s approval for clinical trials of their SK-08 Tablet, aimed at treating chronic kidney disease, and the drug registration approval for Iodixanol Injection, an isotonic X-ray contrast agent with high safety profiles. These developments are set to enhance the company’s product offerings in the treatment of kidney disease and medical imaging diagnosis, addressing significant unmet medical needs and promising market potential.

For further insights into HK:1681 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskConsun Pharma Passes Key Governance Resolution
TipRanks HongKong Auto-Generated NewsdeskConsun Pharmaceutical Plans Governance Changes at EGM
TipRanks HongKong Auto-Generated NewsdeskConsun Pharmaceutical Group Aims for Paperless Compliance
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App